Cited 0 times in
급성백혈병 환자에서 관해유도 항암화학요법 후 발생한 호중구감소증에 대한 류코카인의 효과 : 전향적 이중 비교의 다기관 임상연구
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 유철주 | - |
dc.date.accessioned | 2015-07-15T16:48:58Z | - |
dc.date.available | 2015-07-15T16:48:58Z | - |
dc.date.issued | 2003 | - |
dc.identifier.issn | 2233-5250 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/113654 | - |
dc.description.abstract | Purpose: Neutropenia is common in patients receiving myelotoxic chemotherapy. The aim of this study is to compare the efficacy, safety and adverse events between prophylactically administered Leukokine and Grasin . Methods: An open-label, randomized, phase III study was designed to compare the effects of a subcutaneous injection of Leukokine (CJ Corp.) 100mug/m2 with Grasin (Jeil Pharm. Inc.) in patients receiving induction chemotherapy for acute leukemia. All patients received one dose of G-CSF every day during the study period. Total period of G-CSF injection was not over 14 days. The administration of G-CSF began on day 14 after beginning of chemotherapy under CCG strategy. In other chemotherapies, the injection of G-CSF started on day 1 from end of chemotherapy. Injection of G-CSF stopped after absolute neutrophil count recovery was achieved. Results: The median numbers of times of administration were 9.6(2~14)/cycle for Leukokine and 8.8 (2~14)/cycle for Grasin . The time to needed for neutrophil recovery more than 1,000/mm3 was 6.6 4.9 day and 4.7 4.8 day of the Leukokine and Grasin , respectively (P=0.14). The mean duration of neutropenia less than 500/mm3 was 7.6 5.6 days for Leukokine and 6.1 6.0 days for Grasin (P=0.28). The results for the two groups were also not significantly different in adverse events, physical examination and laboratory findings. Conclusion: Leukokine was safe and well tolerated in these patients population. Injection of Leukokine provided neutrophil recovery with safety and efficacy similar to that provided by Grasin. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.relation.isPartOf | Korean Journal of Pediatric Hematology-Oncology (대한소아혈액종양학회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Acute leukemia | - |
dc.subject.MESH | Leukokine | - |
dc.subject.MESH | Grasin | - |
dc.title | 급성백혈병 환자에서 관해유도 항암화학요법 후 발생한 호중구감소증에 대한 류코카인의 효과 : 전향적 이중 비교의 다기관 임상연구 | - |
dc.title.alternative | Effect of Leukokine in Patients with Acute Leukemia Receiving Induction Chemotherapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아과학) | - |
dc.contributor.googleauthor | 김선영 | - |
dc.contributor.googleauthor | 장필상 | - |
dc.contributor.googleauthor | 이규형 | - |
dc.contributor.googleauthor | 황태주 | - |
dc.contributor.googleauthor | 양창현 | - |
dc.contributor.googleauthor | 유철주 | - |
dc.contributor.googleauthor | 안효섭 | - |
dc.contributor.googleauthor | 신희영 | - |
dc.contributor.googleauthor | 최형수 | - |
dc.contributor.googleauthor | 강형진 | - |
dc.contributor.googleauthor | 이건수 | - |
dc.contributor.googleauthor | 김학기 | - |
dc.contributor.googleauthor | 조빈 | - |
dc.contributor.googleauthor | 정대철 | - |
dc.contributor.googleauthor | 정낙균 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02524 | - |
dc.relation.journalcode | J02096 | - |
dc.subject.keyword | Acute leukemia | - |
dc.subject.keyword | Leukokine | - |
dc.subject.keyword | Grasin | - |
dc.contributor.alternativeName | Lyu, Chuhl Joo | - |
dc.contributor.affiliatedAuthor | Lyu, Chuhl Joo | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 10 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 206 | - |
dc.citation.endPage | 213 | - |
dc.identifier.bibliographicCitation | Korean Journal of Pediatric Hematology-Oncology (대한소아혈액종양학회지), Vol.10(2) : 206-213, 2003 | - |
dc.identifier.rimsid | 44821 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.